Antihypertensive Drugs

The fundamental rationale for treatment is the dose-response relationship between blood pressure reduction and cardiovascular benefit. For each 10 millimeters of mercury reduction in systolic blood pressure, stroke risk falls by approximately 35 percent, coronary artery disease risk by approximately 20 percent, and all-cause mortality by approximately 13 percent. This relationship provides the rationale for combination therapy: larger blood pressure reductions produce proportionally greater benefit, exceeding what any single drug can achieve at tolerable doses.

For Stage 1 hypertension (130 to 139/80 to 89 millimeters of mercury) with low cardiovascular risk, lifestyle modification is tried first with pharmacotherapy added if target is not met in three to six months. With high cardiovascular risk, diabetes, or chronic kidney disease, pharmacotherapy begins alongside lifestyle modification. For Stage 2 hypertension (at or above 140/90), pharmacotherapy is initiated immediately — and when blood pressure is 20/10 millimeters of mercury or more above target, combination therapy is started from the outset rather than titrating a single drug first.

Most patients with Stage 2 hypertension require two or more drugs to reach target blood pressure. Initiating monotherapy and waiting to add a second drug delays goal attainment by months. More importantly, dose-response curves for adverse effects are steeper than for efficacy — combining two drugs at half-standard doses achieves blood pressure reduction equivalent to full-dose monotherapy with fewer adverse effects. Single-pill combinations also improve adherence by 20 to 30 percent compared with separate pills, addressing the single most common cause of treatment failure in clinical practice.

Lifestyle interventions lower blood pressure independently and amplify the efficacy of antihypertensive drugs. The Dietary Approaches to Stop Hypertension eating pattern reduces systolic blood pressure by approximately 11 millimeters of mercury. Sodium restriction below 2.3 grams per day reduces systolic blood pressure by 5 to 6 millimeters of mercury, with greater effect in salt-sensitive individuals. Weight loss reduces systolic blood pressure by approximately 1 millimeters of mercury per kilogram lost. Aerobic exercise at 90 to 150 minutes per week of moderate intensity reduces systolic blood pressure by 5 to 8 millimeters of mercury. Alcohol moderation reduces systolic blood pressure by approximately 4 millimeters of mercury. Lifestyle modifications should be prescribed alongside pharmacotherapy at all stages — not as an alternative to pharmacotherapy in high-risk patients.

Effective combination pairs drugs with complementary, non-redundant mechanisms. Renin-angiotensin-aldosterone system inhibitors reduce angiotensin II-driven vasoconstriction and aldosterone-mediated sodium retention. Diuretics reduce volume and activate the renin-angiotensin-aldosterone system — which is then counteracted by the renin-angiotensin-aldosterone system inhibitor, producing mutual enhancement of both agents. Calcium channel blockers dilate arterioles independently of neurohormonal pathways and are effective even in low-renin states where renin-angiotensin-aldosterone system inhibitors are less potent alone. Beta-blockers reduce cardiac output and renin release, adding benefit in high-sympathetic-tone states. These mechanisms are synergistic rather than merely additive.

The most common cause of apparent resistance is medication non-adherence — rates of non-adherence at one year range from 40 to 60 percent. Other causes include white coat hypertension (elevated office blood pressure but normal ambulatory measurements), suboptimal drug doses below the level needed for adequate response, inadequate diuretic therapy using the wrong agent or wrong dose for renal function, drug interactions from nonsteroidal anti-inflammatory drugs, sympathomimetics, oral contraceptives, or calcineurin inhibitors, and inaccurate blood pressure measurement due to technique errors or improper cuff sizing.

Before labeling a patient as truly resistant: confirm adherence (urine drug levels if needed), perform ambulatory blood pressure monitoring to exclude the white coat effect, review all medications for blood pressure-raising drugs, verify blood pressure technique, and ensure the diuretic component is appropriate — chlorthalidone or indapamide rather than hydrochlorothiazide for superior 24-hour coverage, and a loop diuretic if estimated glomerular filtration rate is below 30 mL/min.

Secondary hypertension is found in 20 to 40 percent of truly resistant cases and should be screened before adding a fourth agent. Obstructive sleep apnea is particularly prevalent — present in approximately 80 percent of patients with resistant hypertension. Essential screening includes the aldosterone-to-renin ratio for primary aldosteronism, plasma metanephrines for pheochromocytoma, renal artery imaging for renovascular hypertension, and polysomnography for obstructive sleep apnea.

The PATHWAY-2 trial (2015) is the definitive evidence base for fourth-line agent selection in resistant hypertension. In a crossover design with 314 patients on established three-drug therapy, spironolactone 25 to 50 mg produced the greatest home systolic blood pressure reduction — 8.7 millimeters of mercury greater than placebo — significantly superior to bisoprolol (4.5 millimeters of mercury greater than placebo) and doxazosin (4.0 millimeters of mercury greater than placebo). The benefit was greatest in patients with the lowest plasma renin, consistent with volume and aldosterone excess as the near-universal mechanism in resistant hypertension.

Spironolactone 25 to 50 mg daily is therefore the evidence-based preferred fourth-line agent for resistant hypertension regardless of whether the aldosterone-to-renin ratio is elevated. If spironolactone is not tolerated due to gynecomastia or hyperkalemia, eplerenone is the alternative selective mineralocorticoid receptor antagonist. If mineralocorticoid receptor antagonist therapy is contraindicated due to severe hyperkalemia or advanced chronic kidney disease, amiloride, bisoprolol, or doxazosin are alternatives. If blood pressure remains uncontrolled on four agents, oral minoxidil with mandatory beta-blocker and loop diuretic, or clonidine with attention to adherence, may be considered.